Active surveillance of serious adverse drug reactions in New Zealand children
- 1NZ Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
- 2Queensland Children's Medical Research Institute, Royal Children's Hospital, University of Queensland, Queensland, Australia
- 3Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand
- Correspondence to Desiree Kunac, NZ Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago, Dunedin 9054, New Zealand; desiree.kunac{at}otago.ac.nz
-
Contributors DK contributed to the conception and design, acquisition, analysis and interpretation of data, drafting and revising the manuscript, and now letter. MT, KG and DR contributed to conception and design, analysis and interpretation of data, and helped with revising the manuscript, and now letter, critically for important intellectual content. All authors approved the final version of the letter.
- Accepted 2 April 2012
- Published Online First 6 May 2012
Children are at risk of developing adverse drug reactions (ADRs),1 yet few are reported through postmarketing surveillance schemes monitoring safety in this vulnerable population.2 We therefore developed an active surveillance system targeting New Zealand paediatricians to enhance serious ADR notifications in children aged <16 years.
A priori, paediatricians were given written case definitions of serious ADRs, which …
